ArticleMolecular and clinical oncology2015
Promoter mutation of tumor suppressor microRNA-7 is associated with poor prognosis of lung cancer.
Article in Molecular and clinical oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- miRNAs as therapeutic predictors and prognostic biomarkers of neoadjuvant chemotherapy in breast cancer: a systematic review and meta-analysis.Breast cancer research and treatment · 2022Pooled it
- The history and function of a circular RNA.Nature communications · 2026Review
- MicroRNA-7: A New Intervention Target for Inflammation and Related Diseases.Biomolecules · 2023Review
- Molecular mechanism of theAnnals of translational medicine · 2023Article
- Optimized thyroid transcription factor-1 core promoter-driven microRNA-7 expression effectively inhibits the growth of human non-small-cell lung cancer cells.Journal of Zhejiang University. Science. B · 2022Article
- Review
- Role of MicroRNA-7 (MiR-7) in Cancer Physiopathology.International journal of molecular sciences · 2022Review
- Cell Behavior of Non-Small Cell Lung Cancer Is at EGFR and MicroRNAs Hands.International journal of molecular sciences · 2021Review
- MiR-7 in Cancer Development.Biomedicines · 2021Review
- MicroRNA-7 negatively regulates Toll-like receptor 4 signaling pathway through FAM177A.Immunology · 2021Article
- Critical Analysis of Genome-Wide Association Studies: Triple Negative Breast CancerInternational journal of molecular sciences · 2020Review
- MicroRNA-7, synergizes with RORα, negatively controls the pathology of brain tissue inflammation.Journal of neuroinflammation · 2020Article
- Clinical value of exhaled breath condensate let-7 in non-small cell lung cancer.International journal of clinical and experimental pathology · 2020Article
- MicroRNA-7: expression and function in brain physiological and pathological processes.Cell & bioscience · 2020Review
- miR-7-5p Promotes Hepatic Stellate Cell Activation by Targeting Fibroblast Growth Factor Receptor 4.Gastroenterology research and practice · 2020Article
- miR-7 Reverses Breast Cancer Resistance To Chemotherapy By Targeting MRP1 And BCL2.OncoTargets and therapy · 2019Article
- Promoter-Operating Targeted Expression of Gene Therapy in Cancer: Current Stage and Prospect.Molecular therapy. Nucleic acids · 2018Review
- MicroRNA-7-5p mediates the signaling of hepatocyte growth factor to suppress oncogenes in the MCF-10A mammary epithelial cell.Scientific reports · 2017Article
- Targeted Expression of miR-7 Operated by TTF-1 Promoter Inhibited the Growth of Human Lung Cancer through the NDUFA4 Pathway.Molecular therapy. Nucleic acids · 2017Article
- Curcumin exerts its antitumor activity through regulation of miR-7/Skp2/p21 in nasopharyngeal carcinoma cells.OncoTargets and therapy · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The significance of promoter mutations of microRNAs (miRNAs) in lung cancer is poorly understood. Recent evidence demonstrated that miRNA-7 (miR-7), a unique member of the miRNA family, exhibited decreased expression and has emerged as an important regulator in lung tumorigenesis. However, the mechanism underlying the downregulation of miR-7 in lung cancer remains largely unknown. In this study, we investigated the sites of mutation of the miR-7 promoter in lung cancer tissues using DNA sequencing. We identified a G→C change at the -617 site (25/39, 64.1%) and an A→G change at the -604 site (20/39, 51.3%) in the miR-7 promoter region in lung cancer tissues. Moreover, the expression of miR-7 in cancer tissue with promoter site mutations was lower compared with that in cancer tissue without mutations (P<0.05). Furthermore, we demonstrated that mutations at these sites may decrease the activity of the miR-7 promoter and alter the expression of miR-7. Notably, mutations at these sites of the miR-7 promoter were found to be closely associated with poor prognosis of lung cancer patients (P=0.037). These data may provide novel insight on the altered expression of specific miRNA molecules in lung cancer and ultimately prove to be helpful in the development of prognostic and therapeutic strategies against lung cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.